With close ties to University of Kansas, Aerobyx, LLC. is structured around development of drugs that target brain bioenergetic fluxes specifically. The intent is to use those drugs to treat persons with Alzheimers Disease. With an emphasize on fundamental biochemical principles such as the law of mass action, and, in addition, exploiting redox ratios - in particular NAD+/NADH coupling that gate some bioenergetic fluxes - the effort is to enhance brain respiration flux,a and/or glycolysis flux to the expected benefit of AD patients.
